Table of Contents
Chromatography Research International
Volume 2014, Article ID 450461, 6 pages
http://dx.doi.org/10.1155/2014/450461
Research Article

Validated HPLC Method for Quantification of Pregabalin in Human Plasma Using 1-Fluoro-2,4-dinitrobenzene as Derivatization Agent

1Department of Human Ecology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran 14155-6451, Iran

Received 29 May 2014; Accepted 14 July 2014; Published 17 August 2014

Academic Editor: Toyohide Takeuchi

Copyright © 2014 Reza Ahmadkhaniha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Rogawski and C. P. Taylor, “Calcium channel α2δ subunit, a new antiepileptic drug target,” Epilepsy Research, vol. 69, no. 3, pp. 183–272, 2006. View at Google Scholar
  2. D. J. Dooley, C. M. Donovan, and T. A. Pugsley, “Stimulus-dependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin,” Journal of Pharmacology and Experimental Therapeutics, vol. 295, no. 3, pp. 1086–1093, 2000. View at Google Scholar · View at Scopus
  3. D. J. Dooley, C. A. Mieske, and S. A. Borosky, “Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin,” Neuroscience Letters, vol. 280, no. 2, pp. 107–110, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fink, D. J. Dooley, W. P. Meder et al., “Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex,” Neuropharmacology, vol. 42, no. 2, pp. 229–236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Zareba, “New treatment options in the management of fibromyalgia: role of pregabalin,” Neuropsychiatric Disease and Treatment, vol. 4, no. 6, pp. 1193–1201, 2008. View at Google Scholar · View at Scopus
  6. J. E. Frampton and R. H. Foster, “Pregabalin,” Drugs, vol. 65, no. 1, pp. 111–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Gray, “Pregabalin in the management of central neuropathic pain,” Expert Opinion on Pharmacotherapy, vol. 8, no. 17, pp. 3035–3041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Zareba, “Pregabalin: a new agent for the treatment of neuropathic pain,” Drugs of Today, vol. 41, no. 8, pp. 509–516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. B. F. Shneker and J. W. McAuley, “Pregabalin: a new neuromodulator with broad therapeutic indications,” Annals of Pharmacotherapy, vol. 39, no. 12, pp. 2029–2037, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. N. Bockbrader, L. L. Radulovic, E. L. Posvar et al., “Clinical pharmacokinetics of pregabalin in healthy volunteers,” The Journal of Clinical Pharmacology, vol. 50, no. 8, pp. 941–950, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. V. V. Vaidya, S. M. Yetal, S. M. N. Roy, N. A. Gomes, and S. S. Joshi, “LC-MS-MS determination of pregabalin in human plasma,” Chromatographia, vol. 66, no. 11-12, pp. 925–928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. U. Mandal, A. K. Sarkar, K. V. Gowda et al., “Determination of pregabalin in human plasma using LC-MS-MS,” Chromatographia, vol. 67, no. 3-4, pp. 237–243, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Nirogi, V. Kandikere, K. Mudigonda, P. Komarneni, and R. Aleti, “Liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry method for the quantification of pregabalin in human plasma,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 877, no. 30, pp. 3899–3906, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. R. Shah, C. Ghosh, and B. T. Thaker, “Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy,” Journal of Advanced Pharmaceutical Technology and Research, vol. 1, no. 3, pp. 354–357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Rastkari, M. Khoobi, A. Shafiee, M. R. Khoshayand, and R. Ahmadkhaniha, “Development and validation of a simple and sensitive HPLC-UV method for the determination of captopril in human plasma using a new derivatizing reagent 2-naphthyl propiolate,” Journal of Chromatography B, vol. 932, pp. 144–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Rastkari and R. Ahmadkhaniha, “Magnetic solid-phase extraction based on magnetic multi-walled carbon nanotubes for the determination of phthalate monoesters in urine samples,” Journal of Chromatography A, vol. 1286, pp. 22–28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Berry and C. Millington, “Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC,” Therapeutic Drug Monitoring, vol. 27, no. 4, pp. 451–456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. T. A. C. Vermeij and P. Edelbroek, “Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 810, no. 2, pp. 297–303, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. R. S. Gujral, S. M. Haque, and S. Kumar, “A novel method for the determination of pregabalin in bulk pharmaceutical formulations and human urine samples,” African Journal of Pharmacy and Pharmacology, vol. 3, no. 6, pp. 327–334, 2009. View at Google Scholar · View at Scopus
  20. T. Wu, Q. Jing, B. Ye, and Y. Shen, “Determination of Pregabalin by HPLC with precolumn derivatization using 1-fluoro-2,4-dinitrobenzene,” Journal of Chemical Engineering of Chinese Universities, vol. 2, pp. 350–353, 2010. View at Google Scholar · View at Scopus
  21. E. Souri, M. Eskandari, M. Barazandeh Tehrani, N. Adib, and R. Ahmadkhaniha, “HPLC determination of pregabalin in bulk and pharmaceutical dosage forms after derivatization with 1-fluoro-2,4-dinitrobenzene,” Asian Journal of Chemistry, vol. 25, no. 13, pp. 7332–7336, 2013. View at Google Scholar · View at Scopus
  22. R. A.-A. Shaalan, “Spectrofluorimetric and spectrophotometric determination of pregabalin in capsules and urine samples,” International Journal of Biomedical Science, vol. 6, no. 3, pp. 260–267, 2010. View at Google Scholar · View at Scopus
  23. H. Jalalizadeh, E. Souri, M. B. Tehrani, and A. Jahangiri, “Validated HPLC method for the determination of gabapentin in human plasma using pre-column derivatization with 1-fluoro-2,4-dinitrobenzene and its application to a pharmacokinetic study,” Journal of Chromatography B, vol. 854, no. 1-2, pp. 43–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Garofolo, “Bioanalytical method validation,” in Analytical Method Validation and Instrument Performance Verification, chapter 8, pp. 105–138, Wiley-Interscience, Hoboken, NJ, USA, 2004. View at Google Scholar
  25. B. Martinc, R. Roskar, I. Grabnar, and T. Vovk, “Simultaneous determination of gabapentin, pregabalin, vigabatrin, and topiramate in plasma by HPLC with fluorescence detection,” Journal of Chromatography B, vol. 962, pp. 82–88, 2014. View at Google Scholar